Hengrui Pharma (600276) Announces A Share Repurchase

Bulletin Express03-02

On 02 March 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276) repurchased 0.62 million of its A Shares for the A Share Employee Stock Ownership Schemes. This transaction represented about 0.01% of the previously outstanding 6.37 billion shares. The repurchase price ranged between RMB 54.25 and RMB 55.63 per share, with a total consideration of RMB 34.16 million.

After the transaction, the number of treasury shares reached 6.16 million, while the total issued shares remained at 6.38 billion. The company disclosed that the repurchase was duly authorized by its board of directors and carried out in compliance with all applicable regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162621372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 17:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162621372","market":"hk","top_or_hot":-1,"title":"Hengrui Pharma (600276) Announces A Share Repurchase","media":"Bulletin Express","content":"<p>On 02 March 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276) repurchased 0.62 million of its A Shares for the A Share Employee Stock Ownership Schemes. This transaction represented about 0.01% of the previously outstanding 6.37 billion shares. The repurchase price ranged between RMB 54.25 and RMB 55.63 per share, with a total consideration of RMB 34.16 million.</p>\n<p>After the transaction, the number of treasury shares reached 6.16 million, while the total issued shares remained at 6.38 billion. The company disclosed that the repurchase was duly authorized by its board of directors and carried out in compliance with all applicable regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma (600276) Announces A Share Repurchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma (600276) Announces A Share Repurchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-02 17:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 02 March 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276) repurchased 0.62 million of its A Shares for the A Share Employee Stock Ownership Schemes. This transaction represented about 0.01% of the previously outstanding 6.37 billion shares. The repurchase price ranged between RMB 54.25 and RMB 55.63 per share, with a total consideration of RMB 34.16 million.</p>\n<p>After the transaction, the number of treasury shares reached 6.16 million, while the total issued shares remained at 6.38 billion. The company disclosed that the repurchase was duly authorized by its board of directors and carried out in compliance with all applicable regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1162621372","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162621372","pubTimestamp":1772444488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 02 March 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276) repurchased 0.62 million of its A Shares for the A Share Employee Stock Ownership Schemes. This transaction represented about...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"恒瑞医药(600276)公告A股回购","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On 02 March 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276) repurchased 0.62 million of its A Shares for the A Share Employee Stock Ownership Schemes. This transaction represented about 0.01% of the previously outstanding 6.37 billion shares. The repurchase price ranged between RMB 54.25 and RMB 55.63 per share, with a total consideration of RMB 34.16 million.\nAfter the transaction, the number of treasury shares reached 6.16 million, while the total issued shares remained at 6.38 billion. The company disclosed that the repurchase was duly authorized by its board of directors and carried out in compliance with all applicable regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162621372","isCrawlerRequest":true}